indiaUpdated: Nov 15, 2020, 14:05 ISTThe first batch of Russia’s Sputnik V vaccine for Covid-19 is likely to reach Kanpur’s Ganesh Shankar Vidyarthi Medical College by next week wherein the vaccine’s Phase 2 and Phase 3 human clinical trials will be conducted. The decision to conduct the human clinical trials of the vaccine was taken after Dr Reddy’s Laboratories got approval from the Drugs Controller General of India (DCGI) in this regard, an official said. Speaking to PTI, college principal R B Kamal said the human clinical trials of the vaccine will start from next week. In September, Dr Reddy’s and the Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, entered into a partnership to conduct clinical trials of Sputnik V vaccine and its distribution in India. On August 11, the Sputnik V vaccine was registered by the Ministry of Health of Russia and became the world’s first registered vaccine against Covid-19 based on the human adenoviral vector platform.

Source: Hindustan Times November 15, 2020 08:20 UTC